View Filing Data

Document and Entity Information - shares	9 Months Ended
Sep. 30, 2018	Oct. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Trading Symbol	ZIOP
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	0001107421
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		142,379,770

BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 31,728	$ 70,946
Receivables	1,021	19
Prepaid expenses and other current assets	14,412	19,818
Total current assets	47,161	90,783
Property and equipment, net	1,344	1,211
Deposits	128	128
Other non-current assets	18,168	13,484
Total assets	66,801	105,606
Current liabilities:
Accounts payable	1,269	4,417
Accrued expenses	9,377	9,909
Contract liability - current portion	49,513	6,389
Deferred rent - current portion	24	141
Total current liabilities	60,183	20,856
Contract liability, net of current portion		35,139
Deferred rent, net of current portion	6	1
Derivative liabilities	2,597	2,424
Total liabilities	62,786	58,420
Commitments and contingencies (Note 6)
Preferred stock, $0.001 par value, 30,000,000 shares authorized
Stockholders' deficit:
Common stock, $0.001 par value; 250,000,000 shares authorized; 142,379,770 and 142,658,037 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	142	143
Additional paid-in capital	604,653	615,493
Accumulated deficit	(761,209)	(712,442)
Total stockholders' deficit	(156,414)	(96,806)
Total liabilities and stockholders' deficit	66,801	105,606
Series 1 Preferred Stock
Current liabilities:
Series 1 preferred stock, $1,200 stated value; 250,000 designated; 130,849 and 119,644 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively; liquidation value of $157.0 million and $143.6 million at September 30, 2018 and December 31, 2017, respectively	$ 160,429	$ 143,992

BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	30,000,000	30,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	142,379,770	142,658,037
Common stock, shares outstanding	142,379,770	142,658,037
Series 1 Preferred Stock
Preferred stock, stated value	$ 1,200	$ 1,200
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	130,849	119,644
Preferred stock, shares outstanding	130,849	119,644
Preferred stock, liquidation preference	$ 157.0	$ 143.6

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Collaboration revenue		$ 1,598	$ 146	$ 4,792
Operating expenses:
Research and development	$ 8,263	11,105	25,935	33,903
General and administrative	4,307	3,571	15,355	10,946
Total operating expenses	12,570	14,676	41,290	44,849
Loss from operations	(12,570)	(13,078)	(41,144)	(40,057)
Other income (expense), net	150	175	462	299
Change in fair value of derivative liabilities	(165)	202	46	(1,292)
Net loss	(12,585)	(12,701)	(40,636)	(41,050)
Preferred stock dividends	(6,074)	(4,903)	(16,656)	(13,939)
Net loss applicable to common stockholders	$ (18,659)	$ (17,604)	$ (57,292)	$ (54,989)
Basic and diluted net loss per share	$ (0.13)	$ (0.13)	$ (0.41)	$ (0.41)
Weighted average common shares outstanding used to compute basic and diluted net loss per share	141,185,404	140,632,297	141,020,025	135,689,364

STATEMENTS OF CHANGES IN PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2018 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital Common Stock	Accumulated Deficit	Series 1 Preferred Stock - Mezzanine
Balance at Dec. 31, 2017	$ (96,806)	$ 143	$ 615,493	$ (712,442)	$ 143,992
Balance (in shares) at Dec. 31, 2017		142,658,037			119,644
Adjustment for implementation of ASU No. 2014-09, Revenue from Contracts with Customers	(8,131)			(8,131)
Stock-based compensation	6,850		6,850
Exercise of employee stock options	$ 240		240
Exercise of employee stock options (Share)	104,167	104,166
Cancelled restricted common stock	$ 0	$ 0	0	0	$ 0
Cancelled restricted common stock (shares)		(70,867)
Repurchase of restricted common stock	(1,275)	$ (1)	(1,274)
Repurchase of restricted common stock (shares)		(311,566)
Preferred stock dividends					$ 16,437
Preferred stock dividends	(16,656)		(16,656)
Preferred stock dividends (shares)					11,205
Net loss	(40,636)			(40,636)
Balance at Sep. 30, 2018	$ (156,414)	$ 142	$ 604,653	$ (761,209)	$ 160,429
Balance (in shares) at Sep. 30, 2018		142,379,770			130,849

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (40,636)	$ (41,050)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	412	259
Stock-based compensation	6,850	6,165
Change in fair value of derivative liabilities	(46)	1,292
(Increase) decrease in:
Receivables	(1,002)	8
Prepaid expenses and other current assets	5,406	(6,660)
Other noncurrent assets	(4,684)	(3)
Increase (decrease) in:
Accounts payable	(3,148)	1,368
Accrued expenses	(532)	1,002
Contract liabilities	(146)	(4,792)
Deferred rent	(112)	(102)
Net cash used in operating activities	(37,638)	(42,513)
Cash flows from investing activities:
Purchases of property and equipment	(545)	(461)
Net cash used in investing activities	(545)	(461)
Cash flows from financing activities:
Proceeds from exercise of stock options	240	99
Repurchase of restricted common stock	(1,275)	(1,042)
Proceeds from issuance of common stock, net		47,270
Net cash provided by (used in) financing activities	(1,035)	46,327
Net increase (decrease) in cash, cash equivalents, and restricted cash	(39,218)	3,353
Cash, cash equivalents, and restricted cash, beginning of period	71,335	81,441
Cash, cash equivalents, and restricted cash, end of period	32,117	84,794
Supplementary disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Series 1 Preferred Stock
Supplementary disclosure of noncash investing and financing activities:
Payment of dividends in preferred stock	$ 16,656	$ 13,939

Business

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Business

1. Business

Overview

ZIOPHARM Oncology, Inc., which is referred to herein as “Ziopharm,” the “Company,” or “we”, is a biopharmaceutical company seeking to develop, acquire, and commercialize, on its own or with partners, a diverse portfolio of immuno-oncology therapies.

The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31.

The Company has operated at a loss since its inception in 2003 and has minimal revenues. The Company anticipates that losses will continue for the foreseeable future. At September 30, 2018, the Company’s accumulated deficit was approximately $761.2 million. Given its current development plans, the Company anticipates cash resources will be sufficient to fund operations into the second quarter of 2019. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing in the near term or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those currently planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development.

As of September 30, 2018, the Company had approximately $31.7 million of cash and cash equivalents. Given its development plans, the Company anticipates cash resources will be sufficient to fund its operations into the second quarter of 2019 and the Company has no committed sources of additional capital. Based on the forecast, management determined that there is substantial doubt regarding our ability to continue as a going concern. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of the Company’s expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than currently anticipated. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its products, management may need to curtail development efforts.

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules and regulations.

It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on March 1, 2018, as amended, or the Form 10-K.

The year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States.

The results disclosed in the statements of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

The Company’s most significant estimates and judgments used in the preparation of its financial statements are:

•

Clinical trial expenses;

•

Collaboration agreements and revenue recognition;

•

Fair value measurements of stock based compensation and Series 1 preferred stock; and

•

Income taxes

Subsequent Events

The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below, the Company did not have any material subsequent events that impacted its financial statements or disclosures.

On October 5, 2018, the Company entered into an exclusive license agreement, or the License Agreement, with Precigen, Inc., or Precigen, a wholly owned subsidiary of Intrexon Corporation, or Intrexon. As between the Company and Precigen, the terms of the License Agreement replace the terms of: (a) that certain Exclusive Channel Partner Agreement by and between the Company and Intrexon, dated January 6, 2011, as amended by the First Amendment to Exclusive Channel Partner Agreement effective September 13, 2011, the Second Amendment to the Exclusive Channel Partner Agreement effective March 27, 2015, and the Third Amendment to Exclusive Channel Partner Agreement effective June 29, 2016, which was subsequently assigned by Intrexon to Precigen; (b) certain rights and obligations pursuant to that certain License and Collaboration Agreement effective March 27, 2015 between the Company, Intrexon and ARES TRADING Trading S.A., or Ares Trading, a subsidiary of Merck KGaA, or Merck, as assigned by Intrexon to Precigen, or the Ares Trading Agreement; (c) that certain License Agreement between the Company, Intrexon and The University of Texas M.D. Anderson Cancer Center, or MD Anderson, with an effective date of January 13, 2015, or the MD Anderson License, which was subsequently assigned by Intrexon and assumed by Precigen effective as of January 1, 2018; and (d) that certain Research and Development Agreement between the Company, Intrexon and MD Anderson with an effective date of August 17, 2015, or the Research and Development Agreement, and any amendments or statements of work thereto.

Pursuant to the terms of the License Agreement, Precigen has granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i) products utilizing Precigen’s RheoSwitch^® gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products, (ii) chimeric antigen receptor, or CAR, products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) a second target, subject to the rights of Merck to pursue such target under the Ares Trading Agreement, and (iii) T-cell receptor, or TCR, products designed for neoantigens for the treatment of cancer. Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Sleeping Beauty technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.

The Company will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products and after a two-year period, the TCR Products.

Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 for the treatment of cancer, referred to as Gorilla IL-12 Products.

Precigen will retain rights to research, develop and commercialize CAR products for all other targets, subject to the rights of Merck to pursue such targets under the Ares Trading Agreement. In addition, Precigen may research, develop and commercialize products for the treatment of cancer outside of the products exclusively licensed to the Company.

In consideration of the licenses and other rights granted by Precigen, the Company will pay Precigen an annual license fee of $100 thousand and has agreed to reimburse Precigen for certain historical costs of the licensed programs up to $1.0 million, payable quarterly.

The Company will make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay Precigen tiered royalties ranging from low-single digit to high-single digit on the net sales derived from the sales of any approved IL-12 Products and CAR Products. The Company will also pay Precigen royalties ranging from low-single digit to mid-single digit on the net sales derived from the sales of any approved TCR Products, up to a maximum royalty amount of $100.0 million in the aggregate. The Company will also pay Precigen 20% of any sublicensing income received by the Company relating to the licensed products.

The Company is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. The Company and Precigen will share the development costs and operating profits for Gorilla IL-12 Products, with the Company responsible for 80% of the development costs and receiving 80% of the operating profits, and Precigen responsible for the remaining 20% of the development costs and receiving 20% of the operating profits.

Precigen will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of Precigen’s CAR products, up to $100.0 million.

In consideration of the Company entering into the License Agreement, Intrexon has forfeited and returned to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement.

In connection with the transaction, the Company incurred approximately $7.0 million of transaction advisory costs with a third-party vendor. Of that amount, approximately $1.0 million was expensed during the three months ended June 30, 2018 and approximately $0.3 million during the three months ended September 30, 2018. The remaining balance of advisory fees is due upon closing of the transaction.

Fair Value Measurements

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 were as follows:


($ in thousands)				Fair Value Measurements at Reporting Date Using
Description	Balance as of September 30, 2018			Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	30,305		$	30,305	$	—	$	—

Liabilities:
Derivative liabilities	$	(2,597	)	$	—	$	—	$	(2,597	)


($ in thousands)				Fair Value Measurements at Reporting Date Using
Description	Balance as of December 31, 2017			Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	66,156		$	66,156	$	—	$	—

Liabilities:
Derivative liabilities	$	(2,424	)	$	—	$	—	$	(2,424	)

The cash equivalents represent deposits in a short term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.

As discussed further in Notes 6, 7, and 9, the Company issued Intrexon 100,000 shares of the Company’s Series 1 preferred stock, a class of preferred stock authorized by the Company’s board of directors, in consideration of the parties entering into a Third Amendment to Exclusive Channel Partner Agreement, or the 2016 ECP Amendment, amending the existing Exclusive Channel Partner Agreement, effective January 6, 2011 and as amended to date, which the Company refers to as the Channel Agreement, and an Amendment to Exclusive Channel Collaboration Agreement, or the 2016 GvHD Amendment, amending the existing Exclusive Channel Collaboration Agreement, effective September 28, 2015, which the Company refers to as the GvHD Agreement. The Series 1 preferred stock are financial liabilities that consist of a conversion option and a redemption feature and are classified as a Level 3 asset. There were no transfers between asset classes during the three and nine months ended September 30, 2018.

At June 30, 2016, the Company’s Series 1 preferred stock was valued using a probability-weighted approach and a Monte Carlo simulation model. Additionally, the monthly dividends issued on the outstanding Series 1 preferred stock are valued using the same probability-weighted approach and a Monte Carlo simulation model. However, there is no adjustment or further revaluation after the initial valuation on the Series 1 preferred stock other than required periodic dividends.

The Company’s Level 3 financial liabilities consist of a conversion option and a redemption feature associated with the Company’s Series 1 preferred stock issued to Intrexon that have been bifurcated from the Series 1 preferred stock and are accounted for as derivative liabilities at fair value. The preferred stock derivative liabilities were valued using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. See Note 6 for additional disclosures on the 2016 ECP Amendment and 2016 GvHD Amendments and Note 9 for additional disclosure on the rights and preferences of the Series 1 preferred stock and valuation methodology.

As discussed in Note 1, in consideration of the Company entering into the License Agreement, Intrexon forfeited and returned to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement. No shares of Series 1 Preferred Stock are currently outstanding as of the filing date of this Quarterly Report.

Revenue Recognition

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Revenue Recognition

5. Revenue Recognition

The Company adopted Accounting Standards Codification, or ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, using the modified retrospective approach on January 1, 2018. The Company completed its assessment and the implementation resulted in a cumulative effect adjustment to accumulated deficit as of January 1, 2018 of approximately $8.1 million and a corresponding increase to the contract liability (formerly deferred revenue). The adjustment to the Company’s financial statements due to the adoption of ASC 606 is related to the Company’s Ares Trading Agreement (see Note 6), which was the Company’s sole open revenue contract outstanding at January 1, 2018.

The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, the Company recognizes revenue in accordance with ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.

The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any development, regulatory or commercial milestones or royalty revenue resulting from any of its collaboration arrangements. Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgement to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.

Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

As it relates to the Ares Trading Agreement (see Note 6), the Company recognized the upfront payment associated with its one open contract as a contract liability upon receipt of payment as it requires deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified in current liabilities. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as contract liabilities, net of current portion. The Company determined that there were three performance obligations; the first performance obligation consists of the license and research development services and the other two performance obligations are material rights as it relates to potential future targets that have not yet been identified. As described above, the transaction price of $57.5 million was allocated to the performance obligations based on their relative standalone selling prices.

There are multiple distinct performance obligations, including material rights; thus, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined based on the prices charged to customers or using expected cost plus margin. Revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure. Furthermore, the Company has not capitalized any contract costs under the guidance in ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers.

The Company does not believe that any variable consideration should be included in the transaction price at the date of adoption of ASC 606 on January 1, 2018 or for the period ended September 30, 2018. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur.

The first performance obligation includes three initial targets, two of which were substantially complete at March 31, 2018. Revenue recognized to date relates to these two targets. There is no remaining contract liability related to these two targets. The third target included in the first performance obligation has not yet been identified; revenue recognition will be deferred until the time that the work on the project begins. No revenue has been recognized related to the material rights, as the option for the material rights has not yet been exercised. The Company has classified the remaining contract liability of $49.5 million as current at September 30, 2018 as all remaining performance obligations are expected to be met in the fourth quarter of 2018, as a result of our License Agreement signed with Precigen subsequent to the balance sheet date (Note 1).

As a result of adopting ASC 606, the Company recorded an $8.1 million adjustment to the opening balance of accumulated deficit in the first quarter of 2018 as a result of the treatment of the up-front consideration received in July 2015 under ASC 605-25 versus ASC 606. Refer below for a summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment:


	Impact of Topic 606 Adoption
	on the Balance Sheet
($ in thousands)	as of January 1, 2018
Description	As reported under Topic 606			Adjustments			Balances without adoption of Topic 606
Contract liability, current portion	$	622		$	(5,767	)	$	6,389
Contract liability, net of current portion	$	49,037		$	13,898		$	35,139
Accumulated deficit	$	(720,573	)	$	(8,131	)	$	(712,442	)

The amount by which each financial statement line item is affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is disclosed below.


	Impact of Topic 606 Adoption
	on the Balance Sheet
($ in thousands)	as of September 30, 2018
Description	As reported under Topic 606			Adjustments		Balances without adoption of Topic 606
Contract liability, current portion	$	49,513		$	12,777	$	36,736
Accumulated deficit	$	(761,209	)	$	12,777	$	(748,432	)


	Impact of Topic 606 Adoption
	on the Statement of Operations
($ in thousands)	for the Three Months Ended September 30, 2018
Description	As reported under Topic 606			Adjustments			Balances without adoption of Topic 606
Collaboration revenue	$	—		$	(1,597	)	$	1,597
Net loss	$	(12,585	)	$	(1,597	)	$	(10,988	)
Basic and diluted net loss per share	$	(0.13	)	$	(0.01	)	$	(0.12	)

	Impact of Topic 606 Adoption
	on the Statement of Operations
($ in thousands)	for the Nine Months Ended September 30, 2018
Description	As reported under Topic 606			Adjustments			Balances without adoption of Topic 606
Collaboration revenue	$	146		$	(4,646	)	$	4,792
Net loss	$	(40,636	)	$	(4,646	)	$	(35,990	)
Basic and diluted net loss per share	$	(0.41	)	$	(0.04	)	$	(0.37	)

	Impact of Topic 606 Adoption
	on the Statement of Cash Flows
($ in thousands)	for the Nine Months Ended September 30, 2018
Description	As reported under Topic 606			Adjustments			Balances without adoption of Topic 606
Net loss	$	(40,636	)	$	(4,646	)	$	(35,990	)
Changes in contract liability	$	—		$	4,792		$	(4,792	)

The most significant change above relates to the Company’s collaboration revenue, which to date has been exclusively generated from its collaboration arrangement with Ares Trading and Precigen, formerly Intrexon (see Note 6). Under ASC 605, the Company accounted for the up-front payment over the estimated period of performance of the research and development services which was estimated to be 9 years. In connection with the adoption of ASC 606, the Company uses cost-based input method to measure progress because such method best reflects the satisfaction of the performance obligation. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to the budgeted costs to complete the research programs. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs. As a result, although the performance obligations noted above and identified under ASC 606 were generally consistent with the units of account identified under ASC 605, the timing of the allocation of the transaction price to the identified performance obligations under ASC 606 differed from the allocations of consideration under ASC 605. Accordingly, the transaction price ultimately allocated to each performance obligation under ASC 606 differed from the amounts allocated under ASC 605. The Company has a full valuation allowance so there was no effect on incomes taxes as a result of this change.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases Prior to December 31, 2012, the Company entered into an operating lease in New York, NY for office space. In accordance with this agreement, the Company entered into a letter of credit in the amount of $388 thousand, naming the Company’s landlord as beneficiary. In January 2012, the Company amended the lease agreement, adding additional office space. The collateral for the letter of credit is restricted cash and recorded in other current assets on the balance sheet as of September 30, 2018. The lease for office space in New York, NY expires in October 2018. On October 17, 2013, the Company entered into a sublease agreement to lease all of its New York office space to a subtenant. The Company remains primarily liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $729 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $2.3 million, less $1.6 million in payments from its subtenant. Total sublease loss was approximately $31 thousand for each of the three-month periods ending September 30, 2018 and 2017. The Company continues to maintain the $388 thousand letter of credit in respect of the New York office space, which is recorded in other current assets on the balance sheet. Prior to December 31, 2012, the Company entered into separate operating lease agreements for various spaces in a building in Boston, MA. In June 2012, the Company re-negotiated a master lease for the Company’s Boston office space to incorporate all three lease agreements under the same master agreement, which was originally set to expire in August 2016. On December 21, 2015 and April 15, 2016, the Company renewed the sublease for the Company’s corporate headquarters in Boston, MA through August 31, 2021. As of September 30, 2018, a security deposit of $128 thousand is included in deposits on the balance sheet. On January 30, 2018, the Company entered into a lease agreement for office space in Houston, TX at MD Anderson. Under the terms of the Houston lease agreement, the Company leases approximately two hundred and ten square feet and is required to make rental payments at an average monthly rate of approximately $1 thousand through April 2021. Upon signing the lease agreement, the Company expensed approximately $40 thousand for rent expense for the period beginning in May 2015 through December 2017. The $40 thousand for rent expense incurred from May 2015 through December 2017, and all future rent expense incurred in Houston, are being deducted from our prepayment at MD Anderson described in the license agreement section below. Total rent expense was approximately $145 thousand and $534 thousand for the three and nine months ended September 30, 2018, respectively. Total rent expense was approximately $177 thousand and $545 thousand for the three and nine months ended September 30, 2017, respectively. The Company records rent expense on a straight-line basis over the term of the lease. Accordingly, the Company has recorded a liability for deferred rent at September 30, 2018 and December 31, 2017 of $30 thousand ($24 thousand as is classified current and $6 thousand as is classified long-term) and $142 thousand ($141 thousand as is classified current and $1 thousand as is classified long-term), respectively, which is recorded in deferred rent on the balance sheets. License Agreements Exclusive Channel Partner Agreement with Precigen for the Cancer Programs On January 6, 2011, the Company entered into the Channel Agreement with Intrexon (which Intrexon subsequently assigned to Precigen), that governs a “channel partnering” arrangement in which the Company uses Precigen’s technology to research, develop and commercialize products in which DNA is administered to humans for expression of anti-cancer effectors for treatment or prophylaxis of cancer, which the Company collectively refers to as the Cancer Program. This Channel Agreement established committees comprising representatives of us and Precigen that governed activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. The Channel Agreement grants the Company a worldwide license to use patents and other intellectual property of Precigen in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which are collectively referred to as the Ziopharm Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of Ziopharm Products, and otherwise is non-exclusive. Under the Channel Agreement, and subject to certain exceptions, the Company was responsible for, among other things, the performance of the Cancer Program, including the development, commercialization and certain aspects of manufacturing of Ziopharm Products. Precigen is responsible for establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Precigen’s patents. After the 2016 ECP Amendment, discussed below, and subject to certain expense allocations and other offsets provided in the Channel Agreement, the Company was obligated to pay Precigen on a quarterly basis 20% of net profits derived in that quarter from the sale of Ziopharm Products, calculated on a Ziopharm Product-by-Ziopharm Product basis. The Company likewise agreed to pay Precigen on a quarterly basis 50% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party’s execution and delivery of the Channel Agreement, the Company entered into a stock purchase agreement with Precigen. As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace the terms of the Channel Agreement. Amendment of Collaborations with Precigen On March 27, 2015, the Company, together with Intrexon, (which Intrexon subsequently assigned to Precigen, Inc.), entered into an ECP Amendment, amending the Channel Agreement. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement discussed below. Pursuant to the ECP Amendment, the chimeric antigen receptor T-cell products to be developed and commercialized pursuant to the Ares Trading Agreement shall be included within the Precigen/Ziopharm collaboration under the Channel Agreement. The ECP Amendment provided that Precigen will pay us fifty percent of all payments Precigen receives for upfronts, milestones and royalties under the Ares Trading Agreement. On June 29, 2016, the Company entered into (1) the 2016 ECP Amendment with Precigen, amending the Channel Agreement, and (2) the 2016 GvHD Amendment, amending the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company was able to pay to Precigen under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Ziopharm Products, calculated on a Ziopharm Product-by-Ziopharm Product basis, subject to certain expense allocations and other offsets provided in the Channel Agreement. The 2016 GvHD Amendment reduced the royalty percentage that the Company would pay to Precigen under the GvHD Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Products (as defined in the GvHD Agreement), subject to certain expense allocations and other offsets provided in the GvHD Agreement. The reductions in the royalty percentages provided by the 2016 ECP Amendment and the 2016 GvHD Amendment do not apply to sublicensing revenue or royalties under the Channel Agreement and GvHD Agreement, nor do they apply to any royalties or other payments made with respect to sublicensing revenue from the existing collaboration with Ares. The Company has announced the decision to stop pursuing the development of engineered cell therapy strategies for targeted treatment of graft-versus-host disease, or GvHD. The Company has reverted the rights under the GvHD Agreement back to Precigen. In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company agreed to issue to Intrexon 100,000 shares of its Series 1 preferred stock. Each share of Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (see Notes 1 and 9). As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace the terms of the Channel Agreement. Exclusive Channel Collaboration Agreement with Precigen for GvHD On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon (which Intrexon subsequently assigned to Precigen) whereby the Company would use Precigen’s technology directed towards in vivo expression of effectors to research, develop and commercialize products for use in the treatment or prevention of GvHD. The GvHD Agreement granted us a worldwide license to use specified patents and other intellectual property of Precigen in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products developed under the GvHD Agreement. The Company paid Intrexon a technology access fee of $10.0 million in cash in October 2015 and agreed to reimburse Intrexon for all related research and development costs pursuant to the GvHD Agreement. The Company has determined that the rights acquired in the GvHD Agreement represent in-process research and development with no alternative future use. Accordingly, the Company recorded a charge of $10.0 million to research and development expense in September 2015. As a result of an in-depth review of the Company’s research and development portfolio, the determination was made that the pursuit of GvHD as an indication was not a material part of its corporate strategy and therefore have decided to stop pursuing the development of engineered cell therapy strategies, used either separately or in combination, for targeted treatment of GvHD. The Company has reverted the rights under the GvHD program back to Precigen. License Agreement—The University of Texas MD Anderson Cancer Center On January 13, 2015, the Company, together with Intrexon (which Intrexon subsequently assigned to Precigen), entered into the MD Anderson License, with MD Anderson. Pursuant to the MD Anderson License, the Company, together with Precigen, hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who became the Company’s Chief Executive Officer in May 2015 and was formerly a tenured professor of pediatrics at MD Anderson and is now currently a visiting scientist under that institution’s policies, as well as either co-exclusive or non-exclusive licenses under certain related technologies such as gamma delta T cells. Pursuant to the terms of the MD Anderson License, MD Anderson received consideration consisting of $50.0 million in shares of common stock (or 10,124,561 shares), and $50.0 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the MD Anderson License, collectively referred to as the License Shares. The License Shares were issued to MD Anderson on March 11, 2015, pursuant to the terms of the MD Anderson License. On January 9, 2015, in order to induce MD Anderson to enter into the MD Anderson License on an accelerated schedule, the Company, together with Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock, in each case based on a trailing 20-day volume-weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the execution of the Letter Agreement, collectively referred to as the Incentive Shares, in the event that the MD Anderson License was entered into on January 14, 2015. The Incentive Shares were issued to MD Anderson on March 11, 2015. On August 17, 2015, the Company, Precigen and MD Anderson entered into the Research and Development Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. Pursuant to the Research and Development Agreement, the Company, Precigen and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year. During the nine months ended September 30, 2018, the Company made payments in the aggregate amount of $2.7 million to MD Anderson compared to $9.3 million during the nine months ended September 30, 2017. The decrease in cash paid to MD Anderson during the nine months ended September 30, 2018 as compared to the same period in the prior year is a result of the final quarterly payment being made to MD Anderson in January 2018 and the result of approved expenditures incurred by us being deducted from the January 2018 quarterly payment. As of September 30, 2018, MD Anderson had used $11.4 million in program related expenses and reimbursed the company $3.7 million related to third party passthrough costs to offset of the prepaid balance for the MD Anderson License and the Research and Development Agreement. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs is $29.6 million, of which $11.5 million is included in other current assets and the remaining $18.1 million is included in non-current assets at September 30, 2018. The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson. The Company determined that the rights acquired in the MD Anderson License represented in process research and development with no alternative future use. Accordingly, the Company recorded a charge of $67.3 million to research and development expense in 2015, representing the fair value of the 11,722,163 shares of its common stock on the date the MD Anderson License was executed. Ares Trading License and Collaboration Agreement On March 27, 2015, the Company, together with Intrexon (which Intrexon subsequently assigned to Precigen) and Ares Trading, signed the Ares Trading Agreement, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Under the collaboration, Ares Trading has elected two CAR⁺ T-cell targets for which the Company will perform certain research activities that will, in part, be funded by Ares Trading. Once these candidates reach investigational new drug, or IND, stage, the programs will be transferred to Ares Trading for clinical development and commercialization. The Company was expected to perform multiple preclinical development programs, each consisting of the development of one product candidate, pursuant to the agreement. Precigen is entitled to receive $5.0 million from Ares Trading payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company was responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development. For the three and nine months ended September 30, 2018, the Company has expensed $36 thousand under the Ares Trading Agreement. Ares Trading paid a non-refundable upfront fee of $115.0 million to Intrexon as consideration for entry into the Ares Trading Agreement. Pursuant to the ECP Amendment, the Company was entitled to receive 50% of the upfront fee, or $57.5 million, which was received from Intrexon in July 2015. The Ares Trading Agreement provides for up to $60.0 million in development milestone payments, up to $148.0 million in regulatory milestone payments and up to $205.0 million in commercial milestone payments for each product candidate. Development milestone payments are triggered upon initiation of a defined phase of clinical research for a product candidate. Regulatory milestone payments are triggered upon approval to market a product candidate by the U.S. Food and Drug Administration (FDA), or other global regulatory authorities. Commercial milestone payments are triggered when an approved pharmaceutical product reaches certain levels of net sales defined in the license. The Ares Trading Agreement also provides for up to $50.0 million of one-time payments upon the achievement of certain technical milestones evidenced by the initiation of a defined phase of clinical research. All development, regulatory and technical milestones are considered substantive based on the contingent nature of the milestone, specifically reviewing factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the milestone as well as the level of effort and investment required. The next potential milestone payment that Precigen could be entitled to receive under the Ares Trading Agreement is a $15.0 million substantive milestone for the initiation of a Phase 1 clinical trial. In addition, to the extent any of the product candidates licensed by Ares Trading are commercialized, Precigen would be entitled to receive royalties ranging from the lower-single digits to the low-teens of net sales derived from the sale of products developed under the agreement. The term of the Ares Trading Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace certain rights and obligations under the Ares Trading Agreement. See Note 5 for detail of the accounting for the Ares Trading Agreement. Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin. The Company issued to the licensors options to purchase 50,222 shares outside of its stock option plans following the successful completion of certain clinical milestones, of which 37,666 shares have vested. The remaining 12,556 shares vested upon enrollment of the first patient in a multi-center pivotal clinical trial. An expense of $87 thousand was charged to research and development expense for the vesting event which occurred in March 2016. This trial was initiated by Solasia Pharma K.K., or Solasia, on March 28, 2016 and triggered a $1.0 million milestone payment to the Company from Solasia which was received in May 2016. An equivalent of $1.0 million milestone payment was subsequently made to MD Anderson and reported net. The Licensors are entitled to receive certain milestone payments. In addition, the Company may be required to make additional payments to the Licensors (as defined in the MD Anderson License) upon achievement of certain other milestones in varying amounts which, on a cumulative basis could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive single digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. Collaboration Agreement with Solasia Pharma K.K. On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia, or the License and Collaboration Agreement. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use in a pan-Asian/Pacific territory comprising Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand. As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. The Company will also be entitled to receive double digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia. The $5.0 million upfront payment received in March 2011 was amortized over the period of the research and development effort, which was completed in March 2016. On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors, as defined in the agreement, will receive a portion of all milestone and royalty payments made by Solasia to us in accordance with the terms of the license agreement with the Licensors. On March 28, 2016, Solasia initiated a multi-center pivotal clinical trial intended to provide substantial evidence of efficacy necessary to support the filing of an application for a New Drug Application, or NDA, for darinaparsin in certain of the territories assigned to Solasia. The initiation of the trial on March 28, 2016 triggered a $1.0 million milestone payment from Solasia to the Company which was received in May 2016. The Company subsequently made an equivalent payment to MD Anderson as the ultimate licensor of darinaparsin (see above). License Agreement with Baxter Healthcare S.A. On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. The final royalty payment of $250 thousand was paid in November 2017. The terms of the Asset Purchase Agreement included an upfront cash payment and an additional payment for existing inventory. No payments were made during the three and nine months ended September 30, 2018 and 2017. Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute On January 10, 2017, the Company announced the signing of a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, for the development of adoptive cell transfer, or ACT,-based immunotherapies genetically modified using the Sleeping Beauty, or SB, transposon/transposase system to express TCRs for the treatment of solid tumors. The principal goal of the CRADA is to develop and evaluate ACT for patients with advanced cancers using autologous peripheral blood lymphocytes, or PBL, genetically modified using the non-viral SB system to express TCRs that recognize specific immunogenic mutations, or neoantigens, expressed within a patient’s cancer. Clinical evaluations of the ability of these SB-engineered PBL to express TCRs reactive against cancer mutations to mediate cancer regression in patients with metastatic disease will be performed. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with researchers at the Company and Precigen. The Company’s remaining obligation, as of September 30, 2018, for this CRADA is $3.1 million over the next two years, payable in $625 thousand payments on a quarterly basis. During the three and nine months ended September 30, 2018, the Company made payments of $625 thousand and $1.9 million, respectively.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions *Collaborations with Intrexon/ Precigen* On January 6, 2011, the Company entered into the Channel Agreement with Intrexon (which Intrexon subsequently assigned to Precigen), (see Note 6). Randal J. Kirk was a director of the Company until October 5, 2018. Mr. Kirk is the chief executive officer, a director, and the largest stockholder of Intrexon. On February 3, 2015, Intrexon purchased 1,440,000 shares of common stock in the Company’s public offering upon the same terms as others that participated in the offering. On March 27, 2015, the Company and Precigen entered into a Second Amendment to the Exclusive Channel Partner Agreement amending the Channel Agreement, which is referred to as the ECP Amendment. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement, which the Company and Precigen entered into with Ares Trading, on March 27, 2015. The ECP Amendment provided that Precigen will pay to the Company 50% of all payments that Precigen receives for upfronts, milestones and royalties under the Ares Trading Agreement (see Note 6). The Amendment also reduces Precigen’s aggregate commitment under a Stock Purchase Agreement that the parties executed in connection with the initial Channel Agreement to purchase the Company’s common stock from $50.0 million to $43.5 million, which has been satisfied. On June 29, 2015, the Company re-purchased 3,711 shares of common stock from Intrexon, at a discount of 5% to the closing price of the Company’s common stock on the date of purchase, which represented fractional shares that resulted from Intrexon’s special stock dividend of the Company’s shares to Intrexon’s shareholders, for $34 thousand. On January 8, 2016, the Company re-purchased an additional 168 shares of common stock from Intrexon for $2 thousand at the same terms as the previous share purchase. On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon (which Intrexon subsequently assigned to Precigen), whereby the Company was granted the right to use Precigen’s technology directed towards in vivo expression of biologics to research, develop and commercialize products for use in the treatment or prevention of GvHD (see Note 6). The Company paid Precigen a technology access fee of $10.0 million in cash in October 2015 and agreed to reimburse Precigen for all research and development costs under the GvHD Agreement. On June 29, 2016, the Company entered into the 2016 ECP Amendment, with Intrexon (which Intrexon subsequently assigned to Precigen), amending the Channel Agreement, and the 2016 GvHD Amendment, amending the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company will pay to Precigen under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Ziopharm Products (as defined in the Channel Agreement), calculated on a Ziopharm Product-by-Ziopharm Product basis, subject to certain expense allocations and other offsets provided in the Channel Agreement. The 2016 GvHD Amendment reduced the royalty percentage that the Company would pay to Precigen under the GvHD Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Products (as defined in the GvHD Agreement), subject to certain expense allocations and other offsets provided in the GvHD Agreement. The reductions in the royalty percentages provided by the 2016 ECP Amendment and the 2016 GvHD Amendment do not apply to sublicensing revenue or royalties under the Channel Agreement and GvHD Agreement, nor do they apply to any royalties or other payments made with respect to sublicensing revenue from the Company’s existing collaboration with Merck Serono, the biopharmaceutical business of Merck. In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued Intrexon 100,000 shares of its Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (see Note 9). The holders of the shares of Series 1 preferred stock are entitled to receive a monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per preferred share held by such holder per month divided by the stated value of the preferred shares, rounded down to the nearest whole share (see Note 9). During the three months ended September 30, 2018, the Company issued an aggregate of 3,847 shares of Series 1 preferred stock to Intrexon, the holder of all of the outstanding shares of the Company’s Series 1 preferred stock, as monthly dividend payments. At September 30, 2018, the Company recorded such shares of Series 1 preferred stock at a fair value of $6.1 million which is a component of temporary equity. During the three months ended September 30, 2018, the Company recorded a loss on the change of the derivative liabilities in the amount of $165 thousand. See Notes 9 and 10 for additional discussion regarding the accounting for and valuation of these derivative financial instruments. During the three months ended September 30, 2018, and 2017, the Company expensed $2.0 million and $5.6 million, respectively, for services performed by Precigen. During the nine months ended September 30, 2018, and 2017, the Company expensed $6.7 million and $16.8 million, respectively, for services performed by Precigen. As of September 30, 2018, and 2017, the Company recorded $2.9 million and $5.5 million, respectively, in current liabilities on its balance sheet for amounts due to Precigen. As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace the terms of the Channel Agreement. *Collaboration with Precigen and MD Anderson* On January 13, 2015, the Company, together with Precigen, entered into the MD Anderson License. Pursuant to the MD Anderson License, the Company and Precigen hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel CAR⁺ T-cell therapies arising from the laboratory of Laurence Cooper, M.D., Ph.D., who is now the Company’s Chief Executive Officer and was formerly a professor of pediatrics at MD Anderson and now currently a visiting scientist under that institution’s policies, as well as either co-exclusive or non-exclusive licenses under certain related technologies. In partial consideration for entering into the MD Anderson License, the Company issued MD Anderson an aggregate of 11,722,163 shares of common stock for which the Company incurred a $67.3 million charge recorded in 2015. The Company has determined that the rights acquired in the MD Anderson License represent in-process research and development with no alternative future use. During the three months ending March 31, 2018, the Company made the final quarterly payment of $2.7 million under the Research and Development Agreement, bringing the total aggregate payments to $41.9 million.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2018

Text Block [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:


	For the three months ended September 30,				For the nine months ended September 30,
(in thousands)	2018		2017		2018		2017
Research and development	$	552	$	615	$	1,765	$	1,772
General and administrative		928		1,467		5,085		4,393

Stock-based compensation expense	$	1,480	$	2,082	$	6,850	$	6,165

The Company granted an aggregate of 300,500 and 506,000 stock options during the three and nine months ended September 30, 2018 with a weighted-average grant date fair value of $2.11 and $2.49 per share, respectively. The Company granted an aggregate of 593,500 and 859,000 stock options during the three and nine months ended September 30, 2017 with a weighted-average grant date fair value of $4.29 and $4.34 per share, respectively.

On February 15, 2018, the Company extended the contractual life of 751,667 fully vested stock options held by one officer of the Company by an additional 9 months. Additionally, on March 12, 2018, the Company extended the contractual life of 117,500 fully vested stock options held by a director. These extensions resulted in additional stock-based compensation expense of $481 thousand in the nine months ended September 30, 2018.

On September 18, 2018, the Company extended the contractual life of 92,500 fully vested stock options held by a director of the Company by approximately 9 months and 167,500 fully vested stock options held by another director of the Company by approximately 21 months. These extensions resulted in additional stock-based compensation expense of $117 thousand in the three and nine months ended September 30, 2018. Furthermore, the Company accelerated the vesting of 34,516 shares of restricted stock and recorded an adjustment of ($12) thousand in the three and nine months ended September 30, 2018.

The Company recognizes forefeitures as they occur. For the three months ended September 30, 2018 and 2017, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:


	For the three months ended September 30,
	2018	2017
Risk-free interest rate	2.82 - 2.98%	1.88 - 2.01%
Expected life in years	6	6
Expected volatility	82.27 - 83.08%	80.82 - 80.95%
Expected dividend yield	0	0

Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2018 is as follows:


(in thousands, except share and per share data)	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2017		3,852,135		$	5.12
Granted		506,000			3.50
Exercised		(104,167	)		2.30
Cancelled		(184,500	)		5.77

Outstanding, September 30, 2018		4,069,468		$	5.24		6.17	$	576

Options exercisable, September 30, 2018		2,924,501		$	5.13		4.98	$	498

Options exercisable, December 31, 2017		2,925,502		$	5.12		5.58	$	1,152

Options available for future grant		5,053,295

At September 30, 2018, total unrecognized compensation costs related to unvested stock options outstanding amounted to $4.1 million. The cost is expected to be recognized over a weighted-average period of 1.55 years.

In September 2017, the Company issued a stock option award as an inducement grant for the purchase of an aggregate of 500,000 shares of the Company’s common stock, outside of the 2012 Plan, at an exercise price of $6.19 per share. The inducement grant is excluded from the option activity table above.

A summary of the status of unvested restricted stock for the nine months ended September 30, 2018 is as follows:


	Number of Shares			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2017		1,808,559		$	5.74
Granted		—			—
Vested		(573,340	)		7.61
Cancelled		(70,867	)		5.07

Non-vested, September 30, 2018		1,164,352		$	4.85

At September 30, 2018, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $3.5 million. The cost is expected to be recognized over a weighted-average period of 1.48 years.

Preferred Stock

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Preferred Stock

9. Preferred Stock

The Company has 30,000,000 shares of preferred stock authorized, of which, 250,000 shares are designated as Series 1 preferred stock.

On June 29, 2016, the Company entered into the 2016 ECP Amendment and 2016 GvHD Amendment with Intrexon (which Intrexon subsequently assigned to Precigen), (see Note 6). In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued to Intrexon 100,000 shares of its newly designated Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization.

The Series 1 preferred stock has the following rights and preferences and certain other rights, preferences, privileges and obligations. See Note 1 for discussion of subsequent transaction regarding Series 1 preferred stock.

Conversion

All shares of Series 1 preferred stock shall automatically convert into shares of common stock upon the public announcement of the first approval in the United States of (i) a Ziopharm Product under the Channel Agreement, (ii) a Product under the GvHD Agreement or (iii) a Product under the Ares Trading Agreement, which the Company refers to as the Conversion Event Date. On the second business day following the Conversion Event Date, each share of Series 1 preferred stock shall convert into a number of shares of common stock equal to the stated value of such Series 1 preferred stock, divided by the greater of (i) the volume weighted average closing price of common stock as reported by The Nasdaq Stock Market, LLC over the 20 trading days ending on the Conversion Event Date or (ii) $1.00 per share; however, without shareholder approval in accordance with the Nasdaq listing rules, the Company will not affect any conversion of the Series 1 preferred stock into shares of common stock in excess of 19.9% of the lesser of (i) the pre-transaction outstanding shares of common stock or (ii) the outstanding shares of common stock at the time of conversion. In addition, without shareholder approval in accordance with the Nasdaq listing rules, the Company will not affect any conversion of the Series 1 preferred stock into common stock to the extent that the number of shares of common stock issued in such conversion would constitute a change of control under the Nasdaq listing rules.

Dividends

The Series 1 preferred stock provides for a monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per share, per month divided by the stated value per share, or the PIK Dividend; provided, that if any shares of Series 1 preferred stock are not converted on the Conversion Event Date (discussed below), then the rate of the PIK Dividend on all remaining unconverted shares of Series 1 preferred stock shall automatically increase from $12.00 to $24.00 per share, per month.

Liquidation Preference

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets prior to the conversion of the Series 1 preferred stock into shares of common stock, then the Series 1 preferred stock will participate in the proceeds of the transaction on a pro rata basis along with common stock, treating the Series 1 preferred stock as if it had been converted into a number of shares of common stock equal to the aggregate stated value of the Series 1 preferred stock, divided by the volume weighted average closing price of common stock over the 20 trading days ending on the public announcement of such voluntary or involuntary liquidation, dissolution or winding up of the Company or change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets. Alternatively, the Company may redeem the Series 1 preferred stock at a redemption price equal to the pro rata amount that the Series 1 preferred stock would have received if it had been converted using the same formula.

Voting Rights

The Series 1 preferred stock does not have any voting rights except that the Company may not, without the consent of the holders of a majority of the outstanding shares of the Series 1 preferred stock, voting as a separate class, (i) amend, alter or repeal any provision of its Certificate of Incorporation in a manner that adversely affects the powers, preferences or rights of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of the Company’s capital stock; (ii) (A) create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of the Company’s capital stock unless the same ranks junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption, or (B) reclassify, alter or amend any existing security that is junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series 1 preferred in respect of any such right, preference or privilege; or (iii) enter into any transaction (or series of related transactions) the effect of which would adversely affect the holders of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of capital stock.

Analysis

The Company analyzed the features of the Series 1 preferred stock and determined that the conversion option and the Company’s right to redeem the shares at liquidation are embedded derivatives that required bifurcation from the Series 1 preferred stock in accordance with FASB ASC 815, Derivatives and Hedging. The embedded derivatives were valued as described below at $0.9 million. Upon issuance of the shares on July 1, 2016, the Company recorded the fair value of the derivatives as a liability and the fair value of the Series 1 preferred stock of $118.2 million as a component of temporary equity. Furthermore, because of the temporary equity classification, the carrying value of the Series 1 preferred stock will not be accreted to redemption value unless or until its redemption becomes probable.

The fair value of the Series 1 preferred stock was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following:


Risk-free interest rate		1.04	%
Expected dividend rate		0
Expected volatility		70.50	%
Preferred stock conversion limit - percentage of outstanding common stock		19.90	%
Preferred conversion floor price	$	1.00

During the three and nine months ended September 30, 2018, the Company issued an aggregate of 3,847 shares and 11,205, shares of Series 1 preferred stock, respectively, to Intrexon, the holder of all of the outstanding shares of its Series 1 preferred stock, as monthly dividend payments. During the three and nine months ended September 30, 2018, the Company recorded such shares of Series 1 preferred stock at a fair value of $6.1 million and $16.7 million, respectively, which is a component of temporary equity. During the three and nine months ended September 30, 2018, the Company recorded a loss of $165 thousand and a gain of $46 thousand, respectively, on the change of the derivative liabilities (see Notes 1 and 10).

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Text Block [Abstract]

Stock-Based Compensation Expense on All Employee and Non-Employee Awards

The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:


	For the three months ended September 30,				For the nine months ended September 30,
(in thousands)	2018		2017		2018		2017
Research and development	$	552	$	615	$	1,765	$	1,772
General and administrative		928		1,467		5,085		4,393

Stock-based compensation expense	$	1,480	$	2,082	$	6,850	$	6,165

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model

For the three months ended September 30, 2018 and 2017, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:


	For the three months ended September 30,
	2018	2017
Risk-free interest rate	2.82 - 2.98%	1.88 - 2.01%
Expected life in years	6	6
Expected volatility	82.27 - 83.08%	80.82 - 80.95%
Expected dividend yield	0	0

Stock Option Activity under Stock Option Plan

Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2018 is as follows:


(in thousands, except share and per share data)	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2017		3,852,135		$	5.12
Granted		506,000			3.50
Exercised		(104,167	)		2.30
Cancelled		(184,500	)		5.77

Outstanding, September 30, 2018		4,069,468		$	5.24		6.17	$	576

Options exercisable, September 30, 2018		2,924,501		$	5.13		4.98	$	498

Options exercisable, December 31, 2017		2,925,502		$	5.12		5.58	$	1,152

Options available for future grant		5,053,295

Summary of Unvested Restricted Stock

A summary of the status of unvested restricted stock for the nine months ended September 30, 2018 is as follows:


	Number of Shares			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2017		1,808,559		$	5.74
Granted		—			—
Vested		(573,340	)		7.61
Cancelled		(70,867	)		5.07

Non-vested, September 30, 2018		1,164,352		$	4.85

Business - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Oct. 05, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Nature Of Operations [Line Items]
Accumulated deficit		$ (761,209)		$ (712,442)
Cash and cash equivalents		31,728		$ 70,946	$ 84,406
Intrexon Corporation/Precigen
Nature Of Operations [Line Items]
Transaction advisory expenses		$ 300	$ 1,000
Subsequent Event \| Gorilla IL-12 Products
Nature Of Operations [Line Items]
Percentage of development cost shared by other party	80.00%
Percentage of operating profit shared by other party	80.00%
Subsequent Event \| Intrexon Corporation/Precigen
Nature Of Operations [Line Items]
Reimbursement of historical costs	$ 1,000
Additional milestone payment for exclusively licensed program to be paid	52,500
Maximum Royalty payable	$ 100,000
Percentage of sublicensing income	20.00%
Royalty payment to be received	$ 100,000
Transaction advisory costs	7,000
Subsequent Event \| Intrexon Corporation/Precigen \| License
Nature Of Operations [Line Items]
Annual Licensing fee	$ 100
Subsequent Event \| Intrexon Corporation/Precigen \| Gorilla IL-12 Products
Nature Of Operations [Line Items]
Percentage of development cost shared by other party	20.00%
Percentage of operating profit shared by other party	20.00%

Impact of Topic 606 Adoption on Financial Statements (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion	$ 49,513		$ 49,513			$ 6,389
Contract liability, net of current portion						35,139
Accumulated deficit	(761,209)		(761,209)			$ (712,442)
Collaboration revenue			146
Net loss	$ (12,585)	$ (12,701)	$ (40,636)	$ (41,050)
Basic and diluted net loss per share	$ (0.13)	$ (0.13)	$ (0.41)	$ (0.41)
Net loss	$ (12,585)	$ (12,701)	$ (40,636)	$ (41,050)
Changes in contract liability			(146)	$ (4,792)
ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion					$ 622
Contract liability, net of current portion					49,037
Accumulated deficit					(720,573)
Difference between Revenue Guidance in Effect before and after Topic 606 \| ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion	12,777		12,777		(5,767)
Contract liability, net of current portion					13,898
Accumulated deficit	12,777		12,777		$ (8,131)
Collaboration revenue	(1,597)		(4,646)
Net loss	$ (1,597)		$ (4,646)
Basic and diluted net loss per share	$ (0.01)		$ (0.04)
Net loss	$ (1,597)		$ (4,646)
Changes in contract liability			4,792
Calculated under Revenue Guidance in Effect before Topic 606 \| ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion	36,736		36,736
Accumulated deficit	(748,432)		(748,432)
Collaboration revenue	1,597		4,792
Net loss	$ (10,988)		$ (35,990)
Basic and diluted net loss per share	$ (0.12)		$ (0.37)
Net loss	$ (10,988)		$ (35,990)
Changes in contract liability			$ (4,792)

Commitments and Contingencies - Additional Information (Detail)								1 Months Ended				3 Months Ended			9 Months Ended		12 Months Ended				32 Months Ended
	Jun. 29, 2016 $ / shares shares	Sep. 28, 2015 USD ($)	Jan. 13, 2015 USD ($) shares	Jan. 09, 2015 USD ($) shares	Mar. 07, 2011 USD ($)	Jan. 06, 2011	Aug. 24, 2004 Patent	Nov. 30, 2017 USD ($)	May 31, 2016 USD ($)	Sep. 30, 2015 USD ($)	Jul. 31, 2015 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2013 USD ($)	Dec. 31, 2012	Dec. 31, 2011 USD ($)	Dec. 31, 2017 USD ($) $ / shares	Jan. 30, 2018 USD ($) ft²	Dec. 31, 2014 USD ($) shares
Commitments and Contingencies Disclosure [Line Items]
Loss on sublease												$ 145,000		$ 177,000	$ 534,000	$ 545,000					$ 40,000
Deferred rent - current portion												24,000			24,000						141,000
Deferred rent-non-current portion												6,000			6,000						1,000
Deferred rent liability net												30,000			30,000						142,000
Research and Development Expense												8,263,000		11,105,000	25,935,000	33,903,000
Cash balance												$ 31,728,000		84,406,000	$ 31,728,000	84,406,000					$ 70,946,000
Series 1 Preferred Stock
Commitments and Contingencies Disclosure [Line Items]
Preferred stock, stated value \| $ / shares												$ 1,200			$ 1,200						$ 1,200
Intrexon Corporation/Precigen \| Series 1 Preferred Stock
Commitments and Contingencies Disclosure [Line Items]
Issuance of common stock in licensing agreement, shares \| shares	100,000											3,847			11,205
Preferred stock, stated value \| $ / shares	$ 1,200
ECP Channel Agreement \| Intrexon Corporation/Precigen \| Quarterly Payment
Commitments and Contingencies Disclosure [Line Items]
Royalty percentage of net profit						20.00%
Percentage of revenue agreed to pay which is obtained from sublicensor						50.00%
ECP Channel Agreement \| Intrexon Corporation/Precigen \| Quarterly Payment \| After Amendment
Commitments and Contingencies Disclosure [Line Items]
Royalty percentage of net profit	20.00%
ECP Channel Agreement \| Intrexon Corporation/Precigen \| Quarterly Payment \| Before Amendment
Commitments and Contingencies Disclosure [Line Items]
Royalty percentage of net profit	50.00%
2016 GvHD Amendment \| Intrexon Corporation/Precigen
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense										$ 10,000,000
2016 GvHD Amendment \| Intrexon Corporation/Precigen \| Quarterly Payment \| After Amendment
Commitments and Contingencies Disclosure [Line Items]
Royalty percentage of net profit	20.00%
2016 GvHD Amendment \| Intrexon Corporation/Precigen \| Quarterly Payment \| Before Amendment
Commitments and Contingencies Disclosure [Line Items]
Royalty percentage of net profit	50.00%
2016 GvHD Amendment \| Intrexon Corporation/Precigen \| License
Commitments and Contingencies Disclosure [Line Items]
Licensing fee		$ 10,000,000
License Agreement \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Issuance of common stock in licensing agreement, shares \| shares															11,722,163		11,722,163
Research and Development Expense															$ 67,300,000		$ 67,300,000
Common stock issued for cash \| shares			10,124,561
Cash consideration for license agreement			$ 50,000,000
License Agreement \| The University of Texas MD Anderson Cancer Center and The Texas A & M University System
Commitments and Contingencies Disclosure [Line Items]
Milestone maximum payment																							$ 4,500,000
Number of products \| Patent							2
Options to purchase common stock \| shares															50,222
Shares vested \| shares																							37,666
License Agreement \| The University of Texas MD Anderson Cancer Center and The Texas A & M University System \| Research and Development Expense
Commitments and Contingencies Disclosure [Line Items]
Issuance of common stock in a license agreement															$ 87,000
License Agreement \| The University of Texas MD Anderson Cancer Center and The Texas A & M University System \| Upon enrollment of the first patient in a multi-center pivotal clinical trial
Commitments and Contingencies Disclosure [Line Items]
Shares vested \| shares																							12,556
License Agreement \| Baxter Healthcare Corporation \| Upon the successful U.S. IND application for indibulin
Commitments and Contingencies Disclosure [Line Items]
Installment payments								$ 250,000				$ 0		0	0	0
License Agreement \| Intrexon Corporation/Precigen \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Cash consideration for license agreement			50,000,000
Letter Agreement \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Common stock issued for cash \| shares				1,597,602
Cash consideration for license agreement				$ 7,500,000
Letter Agreement \| Intrexon Corporation/Precigen \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Cash consideration for license agreement				$ 7,500,000
ARES Trading License
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense												36,000			$ 36,000
Agreement commencement date															2015-05
Agreement termination, notice period															90 days
ARES Trading License \| Development Milestone Payments
Commitments and Contingencies Disclosure [Line Items]
Payments for development, regulatory and commercial milestones per product															$ 60,000,000
ARES Trading License \| Regulatory Milestone Payments
Commitments and Contingencies Disclosure [Line Items]
Payments for development, regulatory and commercial milestones per product															148,000,000
ARES Trading License \| Commercial Milestone Payments
Commitments and Contingencies Disclosure [Line Items]
Payments for development, regulatory and commercial milestones per product															205,000,000
ARES Trading License \| Intrexon Corporation/Precigen
Commitments and Contingencies Disclosure [Line Items]
Milestone payment receivable															$ 5,000,000
Milestone payment receivable period															2 years
Upfront payment received											$ 57,500,000
Percentage of upfront fee payable											50.00%
Milestone maximum payment												50,000,000			$ 50,000,000
ARES Trading License \| Intrexon Corporation/Precigen \| Substantive Milestones
Commitments and Contingencies Disclosure [Line Items]
Potential milestone payment												15,000,000			15,000,000
ARES Trading License \| Intrexon Corporation/Precigen \| License
Commitments and Contingencies Disclosure [Line Items]
Licensing fee											$ 115,000,000
Collaboration Agreement \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Installment payments									$ 1,000,000
Collaboration Agreement \| Solasia
Commitments and Contingencies Disclosure [Line Items]
Upfront payment received					$ 5,000,000
Milestone payment received									$ 1,000,000
Collaboration Agreement \| Solasia \| Development-based milestones
Commitments and Contingencies Disclosure [Line Items]
Expected additional milestone payments to be received															32,500,000
Collaboration Agreement \| Solasia \| Sales-based milestones
Commitments and Contingencies Disclosure [Line Items]
Expected additional milestone payments to be received															$ 53,500,000
Cooperative Research and Development Agreement
Commitments and Contingencies Disclosure [Line Items]
Research and development arrangement Terms															Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
Cooperative Research and Development Agreement \| Minimum
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense			15,000,000
Cooperative Research and Development Agreement \| Maximum
Commitments and Contingencies Disclosure [Line Items]
Research and Development Expense			$ 20,000,000
Cooperative Research and Development Agreement \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Research and Development Service Agreement Payment													$ 2,700,000		$ 2,700,000	$ 9,300,000
Cooperative Research and Development Agreement \| M.D. Anderson Cancer Center
Commitments and Contingencies Disclosure [Line Items]
Funding used to offset costs in research and development expense															11,400,000
Cash balance												29,600,000			29,600,000
Program related expenses being reimbursed															3,700,000
Cooperative Research and Development Agreement \| M.D. Anderson Cancer Center \| Prepaid Expenses and Other Current Assets
Commitments and Contingencies Disclosure [Line Items]
Cash balance												11,500,000			11,500,000
Cooperative Research and Development Agreement \| M.D. Anderson Cancer Center \| Other Noncurrent Assets
Commitments and Contingencies Disclosure [Line Items]
Cash balance												18,100,000			18,100,000
Cooperative Research and Development Agreement \| Intrexon Corporation/Precigen \| National Cancer Institute
Commitments and Contingencies Disclosure [Line Items]
Obligation for payment												3,100,000			3,100,000
Miles stone payment payable												625,000			625,000
Milestone payment paid												625,000			1,900,000
Houston, TX
Commitments and Contingencies Disclosure [Line Items]
Operating lease area \| ft²																						210
Operating leases future minimum monthly payment due through year 2021																						$ 1,000
New York, NY
Commitments and Contingencies Disclosure [Line Items]
Letter of credit												388,000			388,000					$ 388,000
Operating lease expiration month and year																			2018-10
Loss on sublease																		$ 729,000
Obligation for payment																		2,300,000
Sublease revenue from subtenant																		$ 1,600,000
Loss on sublease												31,000		$ 31,000
Boston, MA
Commitments and Contingencies Disclosure [Line Items]
Operating lease expiration month and year																				2016-08
Security deposits												$ 128,000			$ 128,000
Sublease term amendment															Aug. 31, 2021

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands								1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Jun. 29, 2016	Jan. 08, 2016	Sep. 28, 2015	Jun. 29, 2015	Mar. 27, 2015	Feb. 03, 2015	Jan. 06, 2011	Sep. 30, 2015	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2015	Dec. 31, 2017
Related Party Transaction [Line Items]
Company re-purchased additional shares Value													$ 1,275
Change in fair value of derivative liability									$ (165)	$ 183	$ 28	$ 202	46	$ (1,292)
Research and Development Expense									$ 8,263			11,105	$ 25,935	33,903
Series 1 Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, stated value									$ 1,200				$ 1,200			$ 1,200
Temporary equity, fair value									$ 6,100				$ 16,700
License Agreement \| M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)													11,722,163		11,722,163
Research and Development Expense													$ 67,300		$ 67,300
Cooperative Research and Development Agreement \| M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Research and Development Service Agreement Quarterly Payment											2,700		2,700	9,300
Research and Development Service Agreement Aggregate Payments											$ 41,900
Intrexon Corporation/Precigen
Related Party Transaction [Line Items]
Stock issued during period						1,440,000
Percentage of commitment for payments from receipts of upfronts, milestones and royalties					50.00%
Commitment to purchase common stock					$ 43,500		$ 50,000
Stock buy back (Shares)				3,711
Stock buy back				$ 34
Share buy back discount on closing price				5.00%
Company re-purchased additional shares		168
Company re-purchased additional shares Value		$ 2
Amounts expensed for services incurred									2,000			5,600	6,700	16,800
Amount due to related party, current									$ 2,900			$ 5,500	$ 2,900	$ 5,500
Intrexon Corporation/Precigen \| Series 1 Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)	100,000								3,847				11,205
Preferred stock, stated value	$ 1,200
Dividends, preferred stock	$ 12.00
Intrexon Corporation/Precigen \| 2016 GvHD Amendment
Related Party Transaction [Line Items]
Research and Development Expense								$ 10,000
Intrexon Corporation/Precigen \| 2016 GvHD Amendment \| License
Related Party Transaction [Line Items]
Licensing fee			$ 10,000
Intrexon Corporation/Precigen \| 2016 GvHD Amendment \| Quarterly Payment \| After Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	20.00%
Intrexon Corporation/Precigen \| 2016 GvHD Amendment \| Quarterly Payment \| Before Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	50.00%
Intrexon Corporation/Precigen \| ECP Channel Agreement \| Quarterly Payment
Related Party Transaction [Line Items]
Royalty percentage of net profit							20.00%
Intrexon Corporation/Precigen \| ECP Channel Agreement \| Quarterly Payment \| After Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	20.00%
Intrexon Corporation/Precigen \| ECP Channel Agreement \| Quarterly Payment \| Before Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	50.00%

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 18, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 12, 2018	Feb. 15, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted			300,500	593,500	506,000	859,000
Weighted-average grant date fair value			$ 2.11	$ 4.29	$ 2.49	$ 4.34
Additional stock-based compensation expense					$ 481
Accelerated vested of restricted Shares	34,516
Adjustment of restricted vested amount			$ 12		$ 12
Stock options granted exercise price					$ 3.50
Director One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life	92,500
Director Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life	167,500
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life							117,500
Additional stock-based compensation expense			117		$ 117
Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life								751,667
Outside 2012 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted		500,000
Stock options granted exercise price		$ 6.19
Unvested Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to unvested restricted stock outstanding			4,100		$ 4,100
Expected recognition period					1 year 6 months 18 days
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period					1 year 5 months 23 days
Unrecognized stock-based compensation expense related to unvested restricted stock			$ 3,500		$ 3,500

Stock Option Activity under Stock Option Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Shares
Beginning Balance	3,852,135
Granted	506,000
Exercised	(104,167)
Cancelled	(184,500)
Ending Balance	4,069,468	3,852,135
Options exercisable, at end of period	2,924,501	2,925,502
Options available for future grant	5,053,295
Weighted Average Exercise Price
Beginning Balance	$ 5.12
Granted	3.50
Exercised	2.30
Cancelled	5.77
Ending Balance	5.24	$ 5.12
Options exercisable, at end of period	$ 5.13	$ 5.12
Weighted Average Contractual Term (Years)
Outstanding, at end of period	6 years 2 months 1 day
Options exercisable, at end of period	4 years 11 months 23 days	5 years 6 months 29 days
Aggregate Intrinsic Value
Outstanding, at end of period	$ 576
Options exercisable, at end of period	$ 498	$ 1,152

Summary of Unvested Restricted Stock (Detail) - Unvested Restricted Common Stock	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Number of Shares
Beginning Balance \| shares	1,808,559
Granted \| shares	0
Vested \| shares	(573,340)
Cancelled \| shares	(70,867)
Ending Balance \| shares	1,164,352
Weighted Average Grant Date Fair Value
Beginning Balance \| $ / shares	$ 5.74
Granted \| $ / shares	0
Vested \| $ / shares	7.61
Cancelled \| $ / shares	5.07
Ending Balance \| $ / shares	$ 4.85

Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended				9 Months Ended		12 Months Ended
	Jun. 29, 2016	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jul. 01, 2016
Preferred Stock [Line Items]
Preferred stock, shares authorized		30,000,000				30,000,000		30,000,000
Change in derivative liability		$ (165)	$ 183	$ 28	$ 202	$ 46	$ (1,292)
Series 1 Preferred Stock
Preferred Stock [Line Items]
Preferred stock, shares authorized		250,000				250,000		250,000
Preferred stock, stated value		$ 1,200				$ 1,200		$ 1,200
Maximum percentage of common stock issuable upon conversion of preferred stock						19.90%		19.90%
Fair value of Series 1 preferred stock as a component of temporary equity		$ 160,429				$ 160,429		$ 143,992
Temporary equity, fair value		6,100				16,700
Intrexon Corporation/Precigen
Preferred Stock [Line Items]
Embedded conversion liability		$ 900				$ 900
Fair value of Series 1 preferred stock as a component of temporary equity									$ 118,200
Intrexon Corporation/Precigen \| Series 1 Preferred Stock
Preferred Stock [Line Items]
Preferred stock, shares issued	100,000	3,847				11,205
Preferred stock, stated value	$ 1,200
Preferred stock, outstanding shares		0				0
Preferred stock, conversion rate						$ 1.00
Maximum percentage of common stock issuable upon conversion of preferred stock						19.90%
Preferred stock monthly dividend payable (per share)	$ 12.00
Intrexon Corporation/Precigen \| Series 1 Preferred Stock \| Before Conversion Event Date
Preferred Stock [Line Items]
Preferred stock monthly dividend payable (per share)						$ 12.00
Intrexon Corporation/Precigen \| Series 1 Preferred Stock \| Remaining Unconverted Shares
Preferred Stock [Line Items]
Preferred stock monthly dividend payable (per share)						$ 24.00

Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 31,728	$ 70,946	$ 84,406
Restricted cash included in prepaid expenses and other current assets	389
Restricted cash included in other non-current assets			388
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 32,117	$ 71,335	$ 84,794	$ 81,441

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	58,317,741	27,851,409
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,569,468	4,122,335
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,164,352	1,330,492
Series 1 Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	52,583,921	22,398,582

Net Loss per Share - Additional Information (Detail) - Intrexon Corporation/Precigen - Series 1 Preferred Stock	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Earnings Loss Per Share [Line Items]
Number of shares converted into common stock \| shares	52,583,921
Preferred stock, conversion rate \| $ / shares	$ 1.00

Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model (Detail) - Series 1 Preferred Stock - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Preferred stock conversion limit - percentage of outstanding common stock	19.90%	19.90%
Preferred conversion floor price	$ 1.00	$ 1.00
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	1.04%
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	0.00%	0.00%
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	70.50%

Fair Values of Derivative Instruments to be classified as Derivative Liabilities on Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 2,597	$ 2,358	$ 2,469	$ 2,424
Liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 2,597

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 30,305	$ 66,156
Derivative liabilities	(2,597)	(2,424)
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	30,305	66,156
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ (2,597)	$ (2,424)

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate, Minimum	2.82%	1.88%
Risk-free interest rate, Maximum	2.98%	2.01%
Expected life in years	6 years	6 years
Expected volatility, Minimum	82.27%	80.82%
Expected volatility, Maximum	83.08%	80.95%
Expected dividend yield	0.00%	0.00%

Derivative Financial Instruments - Additional Information (Detail)	Sep. 30, 2018 shares
Intrexon Corporation/Precigen \| Series 1 Preferred Stock
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Preferred stock, outstanding shares	0